Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Stock Information for Aclaris Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.